Carbapenem + β-lactamase inhibitor
Meropenem with vaborbactam
Brand names: Vaborem
Adult dose
Dose: 2g/2g IV every 8h (3-hour infusion); refer to BNF for renal dose
Route: IV
Frequency: q8h
Dose adjustments
Renal
Mandatory — refer to BNF
Clinical pearls
- Activity against KPC-producing carbapenem-resistant Enterobacterales; specialist micro/ID
Contraindications
- Carbapenem hypersensitivity
- Severe penicillin allergy
Side effects
- Headache
- GI upset
- Phlebitis
- Seizures (rare)
- C. difficile
Interactions
- Valproate (avoid)
- Probenecid
Monitoring
- U&E
- LFTs
- FBC
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/meropenem-with-vaborbactam/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023